Internal Medicine, Gastroenterology · Atlantis, FL
NPI
1770539850
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
5401 S Congress Ave, # 211
Atlantis, FL, 33462
Phone (561) 964-8221
Groups this clinician bills Medicare through
Medicare paid, 2024
$146K
1,438 services
Medicare patients, 2024
710
Average age 77
Drug cost, 2024
$1.6M
2,665 prescriptions
Company payments, 2025
$1,689
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas Rosenfield was code 99214 (office e&m - established), 602 times for 394 patients. In total Thomas Rosenfield billed 1,438 services in 25 codes, and Medicare paid $146K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-01-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 602 | 394 | $93.82 | $56K |
| 99213 Office E&M - Established | Office | 254 | 213 | $67.02 | $17K |
| 99204 Office E&M - New | Office | 157 | 157 | $122.47 | $19K |
| 43239 Upper GI Endoscopy | Facility | 101 | 101 | $62.77 | $6,340 |
| 45385 Colonoscopy - Lesion Removal | Facility | 87 | 87 | $213.96 | $19K |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 59 | 59 | $187.54 | $11K |
| 99203 Office E&M - New | Office | 42 | 42 | $71.45 | $3,001 |
| 45380 Lower GI Endoscopy - Other | Facility | 35 | 35 | $131.39 | $4,599 |
| 43248 Upper GI Endoscopy | Facility | 27 | 27 | $104.73 | $2,828 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 20 | 20 | $183.62 | $3,672 |
| 99202 Office E&M - New | Office | 12 | 12 | $38.63 | $464 |
By year: 2022 $159K for 1,525 services; 2023 $213K for 4,665 services; 2024 $146K for 1,438 services.
Medicare prescription drug claims, 2024
In 2024, the drug Thomas Rosenfield prescribed most often to Medicare patients was Famotidine, with 959 prescriptions and refills. In total Thomas Rosenfield wrote 2,665 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Famotidine Generic | 959 | 2,230 | 312 | $14K |
| Omeprazole Generic | 312 | 768 | 113 | $4,416 |
| Pantoprazole Sodium Generic | 249 | 625 | 85 | $2,775 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 230 | 230 | 224 | $15K |
| Mesalamine Generic | 61 | 125 | 16 | $25K |
| Esomeprazole Magnesium Generic | 51 | 108 | 19 | $2,172 |
| Linzess Linaclotide | 48 | 78 | 19 | $41K |
| Creon Lipase/Protease/Amylase | 40 | 69 | 14 | $179K |
| Dicyclomine Hcl Generic | 40 | 71 | 18 | $883 |
| Metronidazole Generic | 38 | 42 | 32 | $318 |
| Balsalazide Disodium Generic | 31 | 63 | Under 11 | $7,344 |
| Metoclopramide Hcl Generic | 31 | 41 | Under 11 | $177 |
| Ursodiol Generic | 30 | 54 | Under 11 | $4,544 |
| Sutab Sod Sulf/Pot Chloride/Mag Sulf | 22 | 22 | 21 | $3,595 |
| Stelara Ustekinumab | 22 | 26 | Under 11 | $592K |
Brand drugs: 330 claims; generic drugs: 2,335 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas Rosenfield $1,689 ($1,689 in general payments such as food, travel and fees) from 17 companies. The largest payer was Abbvie Inc. with $419.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 21 | $419 |
| Madrigal Pharmaceuticals MDGL | 7 | $209 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 6 | $208 |
| Gilead Sciences, Inc. GILD | 2 | $164 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 6 | $131 |
| Janssen Biotech, Inc. JNJ | 5 | $108 |
| Ardelyx, Inc. ARDX | 3 | $76.62 |
| Genzyme Corporation SNY | 2 | $70.68 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 2 | $57.19 |
| Novo Nordisk Inc NVO | 2 | $42.53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.